More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Researchers at the University of Illinois Chicago have developed an elective course that can quickly transform fourth-year medical students from functional AI novices to budding AI experts.
Findings from the SOLVE-CRT study were presented to attendees at Heart Rhythm 2023. "Our results showed the study was safe, effective and feasible," Singh said.
Trauma patients who present with poor blood flow and suspected abdominal hemorrhage are well served by emergency physicians using AI-augmented FAST imaging.
Surveying the landscape of interpretive AI in radiology, two researchers note a yawning gap between great expectations set in the recent past and actual clinical implementations as of spring 2023.
The DurAVR transcatheter heart valve, developed by Minnesota-based Anteris Technologies, was designed to move and perform like a healthy, pre-disease native aortic valve.
The new analysis, published in JAMA, suggests that CT results can help identify medium- and high-risk patients who may need to be considered for statin therapy or other preventive treatments.
